Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data.

Abstract

In the MYF2001 trial, treatment of Janus kinase (JAK) inhibitor-relapsed/refractory intermediate-2 or high-risk myelofibrosis (MF) with imetelstat 9.4 mg/kg every 3 weeks demonstrated encouraging median overall survival of 29.9 months. To provide historical context, external real-world data (RWD) were collected from a study of 96 patients who had discontinued ruxolitinib and were subsequently treated with best available therapy (BAT) at Moffitt Cancer Center. A closely matched cohort was identified using the MYF2001 eligibility criteria, including patients with MF who had discontinued ruxolitinib due to lack or loss of response. Overall survival was measured from time of JAK inhibitor discontinuation to death or censored at last follow-up. To improve comparability, propensity score weighting approaches using average treatment effect for overlap population (ATO) and stabilized inverse probability treatment weighting (sIPTW) were used for 10 critical baseline covariates. Fifty-seven patients treated with imetelstat 9.4 mg/kg from MYF2001 and 38 patients treated with BAT from RWD were analyzed with improved balanced baseline covariates after propensity score adjustment, showing significantly lower risk of death with imetelstat compared with BAT (hazard ratio: 0.35; p = 0.0019). With sIPTW, results were similar. Results of sensitivity analyses were consistent with the primary analysis. In conclusion, treatment with imetelstat was associated with longer overall survival compared to BAT (30 vs 12 months, respectively) in closely matched patients with MF after JAK inhibitor failure, warranting further evaluation of imetelstat in this poor-prognosis patient population.

• Authors: Andrew T Kuykendall, Libo Sun, John Mascarenhas, Jean-Jacques Kiladjian, Alessandro M Vannucchi, Julia Wang, Qi Xia, Eugene Zhu, Faye Feller, Aleksandra Rizo, Jacqueline Bussolari, Ying Wan, Rami Komrokji
• Journal: Annals of hematology (Ann Hematol) Vol. 101 Issue 1 Pg. 139-146 (Jan 2022) ISSN: 1432-0584 [Electronic] Germany
• PMID: 34622316 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Chemical References

• Nitriles
• Oligonucleotides
• Protein Kinase Inhibitors
• Pyrazoles
• Pyrimidines
• ruxolitinib
• Janus Kinases
• imetelstat

Topics

• Aged
• Female
• Humans
• Janus Kinases (antagonists & inhibitors)
• Male
• Middle Aged
• Nitriles (adverse effects, therapeutic use)
• Oligonucleotides (adverse effects, therapeutic use)
• Primary Myelofibrosis (drug therapy, epidemiology)
• Propensity Score
• Protein Kinase Inhibitors (adverse effects, therapeutic use)
• Pyrazoles (adverse effects, therapeutic use)
• Pyrimidines (adverse effects, therapeutic use)
• Secondary Prevention
• Survival Analysis